Lexicon Pharmaceuticals, Inc. (LXRX) Profit Margins
Over the twelve months to 2026-06-30, Lexicon Pharmaceuticals, Inc. (LXRX) had operating margin -131.4%, net margin -147.4%, free cash flow margin -156.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LXRXLexicon Pharmaceuticals, Inc.Follow LXRX — free
—
Price chart with a free account
- Market cap
- 631.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | 97.9% | 96.1% | 99.0% | 92.0% | 100.0% | 100.0% | 92.9% | 98.0% | 99.4% | — | |
| Operating margin | -6170.6% | -9955.5% | -4607.2% | -439.2% | 1.1% | -160.5% | -142.5% | -163.4% | 43.9% | -199.2% | -29224.8% | -72489.2% | -14265.0% | -634.2% | -98.2% | -131.4% | |
| Net margin | -6285.3% | -10120.4% | -4686.1% | -438.8% | -3.6% | -165.8% | -134.1% | -190.7% | 40.4% | -244.1% | -29449.0% | -73341.0% | -14710.9% | -644.8% | -101.1% | -147.4% | |
| FCF margin | -4821.2% | -8719.2% | -4176.4% | -331.2% | 141.4% | -221.9% | -202.4% | -235.3% | 35.3% | -596.2% | -29610.1% | -64875.5% | -13485.6% | -578.5% | -136.2% | -156.7% |
USD millions · SEC XBRL
Lexicon Pharmaceuticals, Inc. — questions
- What is Lexicon Pharmaceuticals, Inc.'s operating margin?
- -131.4% over the twelve months to 2026-06-30.
- What is Lexicon Pharmaceuticals, Inc.'s net profit margin?
- -147.4% over the twelve months to 2026-06-30.
Every figure on this page comes from Lexicon Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.